Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03590652 · ClinicalTrials.gov registry record · Phase 2
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
A Phase 2 study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03590652 is a Phase 2 study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 23 participants.
The verdict
NCT03590652, a Phase 2 study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Ixazomib
- DRUG Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-10-17 |
| Est. Completion | 2025-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03590652
The ClinicalTrials.gov registry entry for NCT03590652 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT03590652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03590652 about?
NCT03590652 is a clinical study titled "Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma". The purpose of this study is to determine the overall response rate of patients with Multiple Myeloma to the combination of Daratumumab, Ixazomib, Pomalidomide and Dexamethasone.
What is the current status of trial NCT03590652?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2018-10-17. Estimated completion is 2025-07-02.
What interventions are being tested in trial NCT03590652?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Ixazomib (DRUG), Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML) (DRUG).
Who is sponsoring clinical trial NCT03590652?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.